"We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and ...

Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...

There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $0.8 million, ...

As life returns to normal following the global disruptions caused by Covid-19, its long-term health effects have started surfacing. A recent study pu ...

Detailed price information for Eliem Therapeutics Inc (ELYM-Q) from The Globe and Mail including charting and trades.

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Kidney involvement is one of the major factors of morbidity and mortality in systemic lupus erythematosus (SLE ... Ye Yu and Xinyue Lian for clinical support (Renji Hospital, Shanghai Jiao Tong ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), retaining the price target of ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

The primary objective is to evaluate the safety of CLN-978 for the treatment of active moderate to severe SLE, with secondary ...